So here's a nice Friday surprise for biotech investors: Rocket Pharmaceuticals Inc. (RCKT) shares are taking off in premarket trading. The reason? The FDA just gave the green light to Kresladi, the company's gene therapy for a rare and serious pediatric immune deficiency. This isn't just any approval—it's the first gene therapy ever approved for this condition, which means Rocket gets to plant its flag in some pretty significant medical territory.

But wait, there's more. Along with the approval comes one of those fancy FDA vouchers—a Rare Pediatric Disease Priority Review Voucher. Think of it as a golden ticket that Rocket can sell to another company that wants to jump the line for their own drug review. That sale could mean a nice cash infusion, which is always welcome news for a biotech firm trying to fund its growth plans.

How This Gene Therapy Actually Works

Let's talk about what Kresladi actually does. It's for kids with severe leukocyte adhesion deficiency-I (LAD-I), which is a mouthful but basically means their white blood cells can't fight infections properly due to a genetic mutation. The therapy takes the patient's own blood stem cells, fixes the broken gene in the lab, and then puts them back in. One dose, delivered by IV, aims to restore the immune system's ability to do its job.

The clinical data looks pretty compelling. In the Phase 1/2 study, all patients were alive at 12 months post-treatment (and remained alive throughout follow-up). They saw fewer serious infections, their skin lesions improved, and their wounds actually started healing better. Perhaps most importantly for a gene therapy, it was well-tolerated with no treatment-related serious adverse events. That's the kind of safety profile that makes regulators and investors breathe a little easier.

What the Charts Are Saying

Now for the market mechanics. The stock is currently trading about 12% above its 20-day moving average and nearly 40% above its 100-day average—that's a pretty strong short-term bullish signal. But before you get too excited, remember that the stock is still down about 40% over the past year, so we're talking about a recovery from some pretty depressed levels.

The technical indicators are giving us mixed messages. The RSI sits at 55.68, which is basically neutral territory—not overbought, not oversold. But the MACD is showing bearish pressure at 0.1168, below its signal line. So we've got strength in the price action but some underlying caution in the momentum indicators. Traders are watching key resistance at $5.50 and support at $4.50.

What the Analysts Think

The analyst community seems generally bullish on Rocket, with an average price target of $32.25 and a Buy rating consensus. But the recent moves tell a more nuanced story. Goldman Sachs raised their target to $3.00 but maintained a Sell rating back on March 2. Meanwhile, Cantor Fitzgerald is more optimistic with an Overweight rating and a $10.00 target from February 27. So you've got the full spectrum of opinions here, from cautious to constructive.

As of Friday's premarket action, Rocket shares were up about 10.66% to $5.19. That's the kind of move that happens when you get FDA approval for a first-of-its-kind therapy, especially when it comes with potential financial benefits down the road. For investors, the question now is whether this is just a one-day celebration or the start of a longer-term recovery story.